As of now, oral forms of GLP-1s should not be assumed safe during breastfeeding
PMCID: PMC7938138
Last Published 11.01.2025 Effective Date: 11.01.2025 This policy addresses the use of Ilaris (canakinumab) for the treatment of cryopyrin-associated periodic syndromes (CAPS), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D (Hyper-IgD) syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial mediterranean fever (FMF), Stills disease, systemic juvenile idiopathic arthritis (SJIA) and gout flares
And unlike a gym membership, there is no PMPM overhead, prior authorization process, or pissed off employees eating up HR time and budget
Tirzepatide targets both GLP-1 and another incretin receptor called GIP
In ovarian cancer, mTORC1 regulates glucose metabolism during CD8 + Treg differentiation by modulating HIF1 expression (126)